Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

BACKGROUND: In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases. However, the chronic nature...

Descripción completa

Detalles Bibliográficos
Autores principales: Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G, Niewerth, Denise, van Meerloo, Johan, Cloos, Jacqueline, van der Veer, Michael, Scheffer, George L, Peters, Godefridus J, Chan, Elena T, Anderl, Janet L, Kirk, Christopher J, Zweegman, Sonja, Dijkmans, Ben AC, Lems, Willem F, Scheper, Rik J, de Gruijl, Tanja D, Jansen, Gerrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560160/
https://www.ncbi.nlm.nih.gov/pubmed/23305345
http://dx.doi.org/10.1186/2162-3619-2-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560160/
https://www.ncbi.nlm.nih.gov/pubmed/23305345
http://dx.doi.org/10.1186/2162-3619-2-2

Ejemplares similares